Raze Therapeutics, a biotechnology company leading the discovery and development of a new class of oncology therapeutics that target key metabolic pathways, today announced the appointment of Mikel Moyer, PhD, as Vice President, Molecular Discovery, effective November 1, 2014.
“Dr. Moyer brings proven leadership, deep experience, and a strong record of success to Raze as we build a pipeline of innovative oncology therapeutics that target mitochondrial one-carbon metabolism,” said Jason Rhodes, acting Chief Executive Officer of Raze Therapeutics.
Help employers find you! Check out all the jobs and post your resume.
“Dr. Moyer brings proven leadership, deep experience, and a strong record of success to Raze as we build a pipeline of innovative oncology therapeutics that target mitochondrial one-carbon metabolism,” said Jason Rhodes, acting Chief Executive Officer of Raze Therapeutics.
Help employers find you! Check out all the jobs and post your resume.
